News and Events

Published on: June 8, 2024 Susan Haigney Pharmaceutical Technology, Pharmaceutical Technology, June 2024, Volume 48, Issue 6 Pages: 20-22 The final drug product relies on the quality and reliability of the raw materials used in its production. Raw materials are ...
Read More

Noramco Announces Strategic Alignment with Purisys and Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API and Drug Product Supply Chain Services Provider —The Noramco Group Addresses Critical Supply Chain Challenges, Offering Comprehensive Active Pharmaceutical Ingredients (API) ...
Read More

Noramco Announces the Acquisition of the Cambrex Drug Product Business Unit WILMINGTON, Del. – November 02, 2023 – Noramco, a leading global active pharmaceutical ingredients (API) manufacturer, specializing in controlled substances, announced today it has completed the acquisition of the Cambrex ...
Read More

Noramco Announces Submission and Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Methylnaltrexone Bromide Leverages Company’s Extensive Experience in the Complex Synthesis of Naltrexone-related Products Vertically Integrated Approach Ensures Exceptional Supply Chain Security Wilmington, DE – November 01, ...
Read More

A Letter to the SK Capital Portfolio Community on International Women’s Day 2022 Dear Respected Colleagues: International Women’s Day (IWD), celebrated on this March 8th, is a global day recognizing the social, economic, cultural, and political contributions and achievements of ...
Read More

Leading Producer of Controlled Substance APIs Now Supplying Lisdex API to Generic Drug Manufacturers Preparing for the 2023 Patent Expiry of Top-Selling Branded ADHD Therapy Wilmington, DE – December 3, 2021 – Noramco, LLC, a leading North American producer of ...
Read More

Meet us at DCAT Week March 21 - 24, 2022. The premier business development event for companies engaged in pharmaceutical development and manufacturing. Contact us today to schedule a meeting! Noramco is a global leader in controlled substance APIs for ...
Read More

Two Organizations Will Build on Strengths to Address Differentiated End-Use Markets Wilmington, DE 19 September 2019 – Noramco announced today that its industry-leading cannabinoids business will become a separate company – Purisys, LLC. Purisys will focus exclusively on acting as ...
Read More

Noramco is a proud partner of the International Cannabinoid Derived Pharmaceuticals Summit (iCDP), taking place on September 10-12, 2019 in Boston, MA. Joshua Hoerner will be presenting on Wednesday, September 11, 2019, at 11:45 am. The topic will be on ...
Read More

Amber Burch came to Noramco from a small company environment and thoroughly enjoys working at Noramco, “a very dynamic place to work with a lot of growth”. Working at Noramco and understanding the ins and outs of pharmaceutical manufacturing has ...
Read More